Literature DB >> 8777823

Rheological and microvascular parameters in diabetic peripheral neuropathy.

M J Young1, J L Bennett, S A Liderth, A Veves, A J Boulton, J T Douglas.   

Abstract

1. In order to determine whether rheological changes occur in neuropathic diabetic patients in the absence of smoking, proteinuria, retinopathy or other factors thought to influence haemorheology, three groups of subjects were studied; 24 non-diabetic control subjects (C), 24 non-neuropathic (D) and 24 neuropathic (N) diabetic patients. The groups were matched for age, sex, type and duration of diabetes. No patient or control was a current smoker. No patient had clinically detectable retinopathy or microalbuminuria. Neuropathy was defined as a peroneal conduction velocity < 40 ms-1. All subjects were tested resting semi-recumbent after a light breakfast. 2. There were no significant differences in rheological or microvascular parameters between uncomplicated diabetic patients and non-diabetic control subjects, although peroneal nerve motor conduction velocity was significantly reduced in otherwise uncomplicated diabetic patients [C 51.7 +/- 6.0 ms-1 (mean +/- SD) versus D 45.1 +/- 5.2 ms-1 (P < 0.05 C versus D)]. 3. Transcutaneous oxygen and laser Doppler flux measured at 44 degrees C were higher in control subjects than in neuropathic diabetic patients [C 76 +/- 16 mmHg versus D 71 +/- 10 mmHg versus N 63 +/- 9 mmHg, and C 72 +/- 40 flow units versus D 64 +/- 41 flow units versus N 50 +/- 26 flow units respectively (both P not significant C versus D, P < 0.05 N versus C). 4. Erythrocyte aggregation, plasma viscosity and plasma fibrinogen were all significantly higher in the neuropathic diabetic patients compared with non-diabetic control subjects (all P < 0.05 N versus C). Erythrocyte filtration was not significantly different between groups but was lower in diabetic patients. Whole-blood viscosity (corrected to 45% haematocrit) was significantly higher at both high (100 s-1) and low (1 s-1) shear rates in neuropathic diabetic patients than in non-diabetic control subjects (both P not significant C versus D, P < 0.05 N versus C). There were no significant differences in whole-blood viscosity at a shear rate of 0.01 s-1. 5. In summary, there were no significant differences in rheological or microvascular parameters between matched groups of uncomplicated diabetic patients and control subjects, but erythrocyte aggregation, fibrinogen and plasma and corrected whole-blood viscosity were all significantly different in neuropathic diabetic patients compared with control subjects, as were assessments of microvascular flow. These results suggest that haemorheological changes are associated with disturbances of microvascular flow and diabetic peripheral neuropathy in the absence of other diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777823     DOI: 10.1042/cs0900183

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

1.  Angiopoietin-1/Tie2 signaling pathway contributes to the therapeutic effect of thymosin β4 on diabetic peripheral neuropathy.

Authors:  Lei Wang; Michael Chopp; Alexandra Szalad; XueRong Lu; Mei Lu; Talan Zhang; Zheng Gang Zhang
Journal:  Neurosci Res       Date:  2018-10-13       Impact factor: 3.304

2.  Improvement of diabetic or obese patients' erythrocyte deformability by the program of the brain-oriented obesity control system (BOOCS).

Authors:  K Saito; K Odashiro; T Maruyama; K Akashi; S Mawatari; T Fujino
Journal:  J Physiol Sci       Date:  2012-07-29       Impact factor: 2.781

3.  Physical Properties of Blood Are Altered in Young and Lean Women with Polycystic Ovary Syndrome.

Authors:  Michael J Simmonds; Nikki Milne; Kee Ong; Emily Brotherton; Antony P McNamee; Jarod Horobin; Surendran Sabapathy
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

4.  Painful diabetic peripheral neuropathy: results of a survey characterizing the perspectives and misperceptions of patients and healthcare practitioners.

Authors:  Alesia Sadosky; Joe Hopper; Bruce Parsons
Journal:  Patient       Date:  2014       Impact factor: 3.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.